Stay updated with breaking news from Trial Readouts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Company to host conference call today at 8:00 AM EasternNEW YORK, May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm...
Published: May 10, 2021 NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2021. “We continued to make significant strides in the quarter toward becoming a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with serious CNS conditions. We successfully filed our NDA for AXS-05 for the treatment of MDD with the F...
AXS-07 for migraine, NDA submission (2Q 2021) AXS-05 for smoking cessation, FDA meeting (3Q 2021) AXS-05 for MDD, commercial launch, if approved (2H 2021) Clinical Trial Readouts: Clinical Trial Initiations: Upcoming Scientific Conferences International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting, May 17-20, 2021 American Society for Clinical Psychopharmacology (ASCP) annual meeting, June 1-4, 2021 American Headache Society (AHS) annual meeting, June 3-6, 2021 Upcoming Investor Conferences BofA Health Care Conference, May 11, 2021 (to be webcast) RBC Capital Mar...
Published: Mar 01, 2021 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2020. “The focused execution of the Axsome team made 2020 a year of significant accomplishments. We had successful pre-NDA meetings with the FDA for AXS-05 in major depressive disorder and for AXS-07 in migraine, reported po...